247 related articles for article (PubMed ID: 26200278)
1. Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy.
Evans TL; Cho BC; Udud K; Fischer JR; Shepherd FA; Martinez P; Ramlau R; Syrigos KN; Shen L; Chadjaa M; Wolf M
J Thorac Oncol; 2015 Aug; 10(8):1221-8. PubMed ID: 26200278
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
[TBL] [Abstract][Full Text] [Related]
3. Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer.
Park SH; Cho EK; Kim Y; Kyung SY; An CH; Lee SP; Park JW; Jeong SH; Lee JI; Choi SJ; Park J; Shin DB; Lee JH
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1009-14. PubMed ID: 18259751
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study.
Spigel DR; Waterhouse DM; Lane S; Legenne P; Bhatt K
Clin Lung Cancer; 2013 Jul; 14(4):356-63. PubMed ID: 23391616
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.
Inoue A; Sugawara S; Yamazaki K; Maemondo M; Suzuki T; Gomi K; Takanashi S; Inoue C; Inage M; Yokouchi H; Watanabe H; Tsukamoto T; Saijo Y; Ishimoto O; Hommura F; Nukiwa T
J Clin Oncol; 2008 Nov; 26(33):5401-6. PubMed ID: 18854562
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.
von Pawel J; Jotte R; Spigel DR; O'Brien ME; Socinski MA; Mezger J; Steins M; Bosquée L; Bubis J; Nackaerts K; Trigo JM; Clingan P; Schütte W; Lorigan P; Reck M; Domine M; Shepherd FA; Li S; Renschler MF
J Clin Oncol; 2014 Dec; 32(35):4012-9. PubMed ID: 25385727
[TBL] [Abstract][Full Text] [Related]
7. Effect of topotecan as second-line chemotherapy for small cell lung cancer patients with interstitial lung disease.
Suzuki H; Hirashima T; Kobayashi M; Sasada S; Okamoto N; Uehara N; Matsuura Y; Tamiya M; Morishita N; Higashiguchi M; Tsumori T; Kawase I
J Chemother; 2011 Dec; 23(6):367-70. PubMed ID: 22233823
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer.
Heist RS; Fain J; Chinnasami B; Khan W; Molina JR; Sequist LV; Temel JS; Fidias P; Brainerd V; Leopold L; Lynch TJ
J Thorac Oncol; 2010 Oct; 5(10):1637-43. PubMed ID: 20808253
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer.
Jones S; Thompson D; Barton J; Patton J; Shipley D; Greco FA; Spigel D; Infante J; Burris HA
Clin Lung Cancer; 2008 May; 9(3):154-9. PubMed ID: 18621625
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.
Inoue A; Sugawara S; Maemondo M; Mori Y; Oizumi S; Harada M; Taima K; Morikawa N; Ishida T; Kinoshita I; Watanabe H; Suzuki T; Nakagawa T; Saito R; Nukiwa T
Lung Cancer; 2015 Jul; 89(1):61-5. PubMed ID: 26004087
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.
Nogami N; Hotta K; Kuyama S; Kiura K; Takigawa N; Chikamori K; Shibayama T; Kishino D; Hosokawa S; Tamaoki A; Harita S; Tabata M; Ueoka H; Shinkai T; Tanimoto M
Lung Cancer; 2011 Oct; 74(1):80-4. PubMed ID: 21334093
[TBL] [Abstract][Full Text] [Related]
12. Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: a pooled analysis of topotecan second-line trials.
Ardizzoni A; Tiseo M; Boni L
Eur J Cancer; 2014 Sep; 50(13):2211-8. PubMed ID: 24981975
[TBL] [Abstract][Full Text] [Related]
13. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.
Ardizzoni A; Manegold C; Debruyne C; Gaafar R; Buchholz E; Smit EF; Lianes P; ten Velde G; Bosquee L; Legrand C; Neumaier C; King K;
Clin Cancer Res; 2003 Jan; 9(1):143-50. PubMed ID: 12538462
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy.
Jotte R; Conkling P; Reynolds C; Galsky MD; Klein L; Fitzgibbons JF; McNally R; Renschler MF; Oliver JW
J Clin Oncol; 2011 Jan; 29(3):287-93. PubMed ID: 21135284
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.
Gronlund B; Hansen HH; Høgdall C; Engelholm SA
Cancer; 2002 Oct; 95(8):1656-62. PubMed ID: 12365013
[TBL] [Abstract][Full Text] [Related]
16. [Postmarketing surveillance study on the use of topotecan in small-cell lung cancer. Use of topotecan in a pneumology university department].
Hureaux J; Alizon C; Urban T
Rev Mal Respir; 2012 May; 29(5):680-7. PubMed ID: 22682594
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancer.
Spigel DR; Greco FA; Burris HA; Shipley DL; Clark BL; Whorf RC; Arrowsmith ER; Hainsworth JD
Clin Lung Cancer; 2011 May; 12(3):187-91. PubMed ID: 21663862
[TBL] [Abstract][Full Text] [Related]
18. Topotecan monotherapy for the treatment of relapsed small cell lung cancer in elderly patients: A retrospective analysis.
Imai H; Yamada Y; Minemura H; Sugiyama T; Kotake M; Kaira K; Kanazawa K; Nakamura Y; Kasai T; Shibata Y; Kaburagi T; Minato K;
Thorac Cancer; 2018 Dec; 9(12):1699-1706. PubMed ID: 30281216
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of topotecan plus carboplatin for relapsed SCLC: WJTOG trial.
Kurata T; Kashii T; Takeda K; Seki N; Tsuboi M; Kobayashi M; Satoh T; Nakagawa K; Fukuoka M
J Thorac Oncol; 2009 May; 4(5):644-8. PubMed ID: 19325498
[TBL] [Abstract][Full Text] [Related]
20. Topotecan in the treatment of recurrent small cell lung cancer: an update.
Ardizzoni A
Oncologist; 2004; 9 Suppl 6():4-13. PubMed ID: 15616145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
